Orexigen announces results of phase 3 trial of obesity drug

SAN DIEGO Orexigen Therapeutics said that its phase 3 trial of the drug, Contrave (naltrexone SR/bupropion SR) showed a significant reduction in body weight.

“The results of this trial indicate that additional, clinically significant weight loss can be achieved when Contrave is added to a rigorous program of diet and exercise,” Orexigen CMO Eduardo Dunayevich said in a statement. “We are also very pleased with the safety profile demonstrated by Contrave so far.”

The company plans to submit another approval application for the drug later this year.